LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Nektar Therapeutics

Nektar Therapeutics

Затворен

1.12 -9.68

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.11

Максимум

1.23

Ключови измерители
By Trading Economics
Приходи	-46M
Продажби	-259K 24M
EPS	-0.22
Марж на печалбата	-189.848
Служители	137
EBITDA	-32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+61.29 upside

Дивиденти
By Dow Jones
Следващи печалби	5.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-20M 230M
Предишно отваряне	10.8
Предишно затваряне	1.12

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

N/A / 1.24 Подкрепа & съпротива

Nektar Therapeutics Графика

Свързани новини

5.09.2024 г., 23:29 ч. UTC

Горещи акции

Stocks to Watch: Broadcom, Smith & Wesson Brands, Helen of Troy, Quanex Building Products

5.09.2024 г., 22:58 ч. UTC

Придобивния, сливания и поглъщания

Perseus Mining: Increases Stake in Predictive Discovery to 19.9%

5.09.2024 г., 22:43 ч. UTC

Топ новини

Hunter Biden Agrees to Surprise Guilty Plea in Tax Case -- 4th Update

5.09.2024 г., 22:31 ч. UTC

Топ новини

Trump Proposes 15% Tax Rate for Some Companies and a Role for Elon Musk in Government -- 2nd Update

5.09.2024 г., 22:00 ч. UTC

Топ новини

Trump Proposes 15% Tax Rate for Some Companies and Role for Elon Musk in Government -- Update

5.09.2024 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Avangrid: FERC Approves Iberdrola's Acquisition of Remaining 18.4% Avangrid Stake That It Does Not Currently Own

5.09.2024 г., 21:44 ч. UTC

Придобивния, сливания и поглъщания

Why Berkshire Hathaway Might Stop Selling Bank of America Stock Once It Reaches This Number -- Barrons.com

5.09.2024 г., 21:31 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Salesforce to Buy Data Protection/Data Management Business Own Company -- Update

5.09.2024 г., 21:21 ч. UTC

Топ новини

Hunter Biden Agrees to Surprise Guilty Plea in Tax Case -- 3rd Update

5.09.2024 г., 21:16 ч. UTC

Топ новини

Печалби

Broadcom 4Q Outlook Misses Views After 3Q Outperformance

5.09.2024 г., 20:59 ч. UTC

Печалби

Costco Wholesale Has Another Strong Month. Gas Prices Were the Only Soft Spot. -- Barrons.com

5.09.2024 г., 20:51 ч. UTC

Печалби

Broadcom Narrowly Beats Quarterly Targets, Disappoints With Sales Outlook -- IBD

5.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

5.09.2024 г., 20:47 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

Salesforce to Buy Data Protection/Data Management Business Own Company

5.09.2024 г., 20:43 ч. UTC

Придобивния, сливания и поглъщания

Verizon Bets on Bundling in $20 Billion Frontier Deal. Rivals May be Circling. -- Barrons.com

5.09.2024 г., 20:37 ч. UTC

Придобивния, сливания и поглъщания

Salesforce: No Anticipated Change to FY25 Fincl Guidance >CRM

5.09.2024 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Salesforce: Will Acquire Own for Approximately $1.9B in Cash >CRM

5.09.2024 г., 20:35 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Signs Definitive Agreement To Acquire Own Company >CRM

5.09.2024 г., 20:30 ч. UTC

Печалби

Broadcom Narrowly Beats Quarterly Targets, Disappoints With Sales Outlook -- IBD

5.09.2024 г., 20:27 ч. UTC

Топ новини

Hunter Biden Agrees to Surprise Guilty Plea in Tax Case -- 2nd Update

5.09.2024 г., 20:25 ч. UTC

Топ новини

Dow Industrials, S&P 500 Close Lower Ahead of Crucial Jobs Report -- WSJ

5.09.2024 г., 20:24 ч. UTC

Топ новини

Печалби

Broadcom Stock Drops on a Weak Outlook -- Barrons.com

5.09.2024 г., 20:19 ч. UTC

Топ новини

Bank of America Shared Nonpublic Information With Investors in India, Whistleblower Says -- Update

5.09.2024 г., 20:18 ч. UTC

Печалби

Broadcom Declares Qtr Dividend of 53c >AVGO

5.09.2024 г., 20:17 ч. UTC

Печалби

Broadcom Generated $4.96B in Cash From Ops for 3Q >AVGO

5.09.2024 г., 20:16 ч. UTC

Печалби

Broadcom Sees 4Q Adj EBITDA Guidance of About 64 % of Projected Rev >AVGO

5.09.2024 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.09.2024 г., 20:15 ч. UTC

Печалби

Broadcom 3Q Loss $1.88B >AVGO

Сравнение с други в отрасъла

Ценова промяна

Nektar Therapeutics Прогноза

Ценова цел

By TipRanks

61.29% нагоре

12-месечна прогноза

Среден 2 USD 61.29%

Висок 2 USD

Нисък 2 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Nektar Therapeutics през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Nektar Therapeutics през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 1.24Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bullish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.